Argininosuccinic Aciduria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major argininosuccinic aciduria markets are expected to exhibit a CAGR of 3.3% during 2024-2034.
The argininosuccinic aciduria market has been comprehensively analyzed in IMARC's new report titled "Argininosuccinic Aciduria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Argininosuccinic aciduria is a rare inherited metabolic disorder that primarily affects the urea cycle, which is responsible for removing ammonia from the body. It is characterized by a deficiency of the enzyme argininosuccinate lyase, that is essential to effectively break down certain proteins. The symptoms of this illness can vary widely in severity and age of onset. In some cases, indications may appear shortly after birth, while in others, they may become evident later in infancy or childhood. Individuals suffering from the ailment might experience poor feeding, vomiting, developmental delays, intellectual disabilities, seizures, irritability, lethargy, liver dysfunction, behavioral issues, etc. In extreme instances, the high levels of ammonia in the blood can further lead to serious neurological damage, coma, or even death. The diagnosis of argininosuccinic aciduria typically involves a combination of clinical evaluation, medical history review, and biochemical tests. Furthermore, genetic testing is recommended to identify gene mutations that might be contributing to the underlying disease. A healthcare provider may also perform blood workups to detect the levels of plasma ammonia and confirm the diagnosis.
The increasing cases of genetic mutations, which can reduce or eliminate the activity of specific enzymes, thereby affecting normal bodily processes, are primarily driving the argininosuccinic aciduria market. In addition to this, the inflating utilization of prenatal screening via amniocentesis and chorionic villus sampling to detect certain chromosomal abnormalities related to the urea cycle in the developing fetus is also creating a positive outlook for the market. Moreover, the widespread adoption of nitrogen scavenger drugs, like sodium phenylbutyrate and sodium benzoate, since they can help to convert nitrogen waste into less toxic forms that can be excreted more easily, is further bolstering the market growth. Apart from this, the escalating demand for liver transplant procedures to treat severe disease conditions on account of their numerous benefits, such as normalizing the metabolic process and increasing the survival rate of patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of exogenous arginine supplementation through intravenous infusion, which promotes ammonia detoxification by stimulating the synthesis of urea, is expected to drive the argininosuccinic aciduria market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the argininosuccinic aciduria market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for argininosuccinic aciduria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the argininosuccinic aciduria market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the argininosuccinic aciduria market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the argininosuccinic aciduria market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current argininosuccinic aciduria marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the argininosuccinic aciduria market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the argininosuccinic aciduria market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the argininosuccinic aciduria market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of argininosuccinic aciduria across the seven major markets?
What is the number of prevalent cases (2018-2034) of argininosuccinic aciduria by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of argininosuccinic aciduria by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with argininosuccinic aciduria across the seven major markets?
What is the size of the argininosuccinic aciduria patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of argininosuccinic aciduria?
What will be the growth rate of patients across the seven major markets?
Argininosuccinic Aciduria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for argininosuccinic aciduria drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the argininosuccinic aciduria market?
What are the key regulatory events related to the argininosuccinic aciduria market?
What is the structure of clinical trial landscape by status related to the argininosuccinic aciduria market?
What is the structure of clinical trial landscape by phase related to the argininosuccinic aciduria market?
What is the structure of clinical trial landscape by route of administration related to the argininosuccinic aciduria market?
The argininosuccinic aciduria market has been comprehensively analyzed in IMARC's new report titled "Argininosuccinic Aciduria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Argininosuccinic aciduria is a rare inherited metabolic disorder that primarily affects the urea cycle, which is responsible for removing ammonia from the body. It is characterized by a deficiency of the enzyme argininosuccinate lyase, that is essential to effectively break down certain proteins. The symptoms of this illness can vary widely in severity and age of onset. In some cases, indications may appear shortly after birth, while in others, they may become evident later in infancy or childhood. Individuals suffering from the ailment might experience poor feeding, vomiting, developmental delays, intellectual disabilities, seizures, irritability, lethargy, liver dysfunction, behavioral issues, etc. In extreme instances, the high levels of ammonia in the blood can further lead to serious neurological damage, coma, or even death. The diagnosis of argininosuccinic aciduria typically involves a combination of clinical evaluation, medical history review, and biochemical tests. Furthermore, genetic testing is recommended to identify gene mutations that might be contributing to the underlying disease. A healthcare provider may also perform blood workups to detect the levels of plasma ammonia and confirm the diagnosis.
The increasing cases of genetic mutations, which can reduce or eliminate the activity of specific enzymes, thereby affecting normal bodily processes, are primarily driving the argininosuccinic aciduria market. In addition to this, the inflating utilization of prenatal screening via amniocentesis and chorionic villus sampling to detect certain chromosomal abnormalities related to the urea cycle in the developing fetus is also creating a positive outlook for the market. Moreover, the widespread adoption of nitrogen scavenger drugs, like sodium phenylbutyrate and sodium benzoate, since they can help to convert nitrogen waste into less toxic forms that can be excreted more easily, is further bolstering the market growth. Apart from this, the escalating demand for liver transplant procedures to treat severe disease conditions on account of their numerous benefits, such as normalizing the metabolic process and increasing the survival rate of patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of exogenous arginine supplementation through intravenous infusion, which promotes ammonia detoxification by stimulating the synthesis of urea, is expected to drive the argininosuccinic aciduria market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the argininosuccinic aciduria market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for argininosuccinic aciduria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the argininosuccinic aciduria market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the argininosuccinic aciduria market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the argininosuccinic aciduria market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current argininosuccinic aciduria marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the argininosuccinic aciduria market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the argininosuccinic aciduria market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the argininosuccinic aciduria market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of argininosuccinic aciduria across the seven major markets?
What is the number of prevalent cases (2018-2034) of argininosuccinic aciduria by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of argininosuccinic aciduria by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with argininosuccinic aciduria across the seven major markets?
What is the size of the argininosuccinic aciduria patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of argininosuccinic aciduria?
What will be the growth rate of patients across the seven major markets?
Argininosuccinic Aciduria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for argininosuccinic aciduria drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the argininosuccinic aciduria market?
What are the key regulatory events related to the argininosuccinic aciduria market?
What is the structure of clinical trial landscape by status related to the argininosuccinic aciduria market?
What is the structure of clinical trial landscape by phase related to the argininosuccinic aciduria market?
What is the structure of clinical trial landscape by route of administration related to the argininosuccinic aciduria market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARGININOSUCCINIC ACIDURIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ARGININOSUCCINIC ACIDURIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARGININOSUCCINIC ACIDURIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ARGININOSUCCINIC ACIDURIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARGININOSUCCINIC ACIDURIA - UNMET NEEDS
10 ARGININOSUCCINIC ACIDURIA - KEY ENDPOINTS OF TREATMENT
11 ARGININOSUCCINIC ACIDURIA - MARKETED PRODUCTS
11.1 List of Argininosuccinic Aciduria Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ARGININOSUCCINIC ACIDURIA - PIPELINE DRUGS
12.1 List of Argininosuccinic Aciduria Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ARGININOSUCCINIC ACIDURIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARGININOSUCCINIC ACIDURIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARGININOSUCCINIC ACIDURIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Argininosuccinic Aciduria - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Argininosuccinic Aciduria - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Argininosuccinic Aciduria - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Argininosuccinic Aciduria - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Argininosuccinic Aciduria - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Argininosuccinic Aciduria - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Argininosuccinic Aciduria - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Argininosuccinic Aciduria - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Argininosuccinic Aciduria - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Argininosuccinic Aciduria - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Argininosuccinic Aciduria - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Argininosuccinic Aciduria - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Argininosuccinic Aciduria - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Argininosuccinic Aciduria - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Argininosuccinic Aciduria - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Argininosuccinic Aciduria - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
16 ARGININOSUCCINIC ACIDURIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARGININOSUCCINIC ACIDURIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARGININOSUCCINIC ACIDURIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARGININOSUCCINIC ACIDURIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ARGININOSUCCINIC ACIDURIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARGININOSUCCINIC ACIDURIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ARGININOSUCCINIC ACIDURIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARGININOSUCCINIC ACIDURIA - UNMET NEEDS
10 ARGININOSUCCINIC ACIDURIA - KEY ENDPOINTS OF TREATMENT
11 ARGININOSUCCINIC ACIDURIA - MARKETED PRODUCTS
11.1 List of Argininosuccinic Aciduria Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ARGININOSUCCINIC ACIDURIA - PIPELINE DRUGS
12.1 List of Argininosuccinic Aciduria Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ARGININOSUCCINIC ACIDURIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARGININOSUCCINIC ACIDURIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARGININOSUCCINIC ACIDURIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Argininosuccinic Aciduria - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Argininosuccinic Aciduria - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Argininosuccinic Aciduria - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Argininosuccinic Aciduria - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Argininosuccinic Aciduria - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Argininosuccinic Aciduria - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Argininosuccinic Aciduria - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Argininosuccinic Aciduria - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Argininosuccinic Aciduria - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Argininosuccinic Aciduria - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Argininosuccinic Aciduria - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Argininosuccinic Aciduria - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Argininosuccinic Aciduria - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Argininosuccinic Aciduria - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Argininosuccinic Aciduria - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Argininosuccinic Aciduria - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Argininosuccinic Aciduria - Access and Reimbursement Overview
16 ARGININOSUCCINIC ACIDURIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARGININOSUCCINIC ACIDURIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARGININOSUCCINIC ACIDURIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
